Mitotech SA

Mitotech S.A. is a biotechnology firm headquartered in Luxembourg that specializes in developing innovative drugs for the treatment of age-related disorders. Their drug pipeline includes an ophthalmic drug (Visomitin) and a systemic drug (Plastomitin) that share the same lead compound, SkQ1, which is a potent mitochondria-targeted antioxidant. The company's team consists of a diverse group of experts from various fields, including science, clinical drug development, and business management. By combining their skills and knowledge, they aim to address complex scientific issues, such as cellular oxidative stress, and turn research findings into effective pharmaceutical products. Mitotech S.A.'s ultimate goal is to provide patients worldwide with medications that utilize a novel mechanism of action and deliver highly active antioxidants to mitochondria across a broad range of age-related therapeutic indications.